Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of PCV24 in Children Aged 2 Months to 17 Years
NCT06675032Phase 1Completed
- Sponsor
- Shanghai Reinovax Biologics Co., Ltd.
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Reinovax PCV24 in pneumococcal infection (10 arms), sponsored by Shanghai Reinovax Biologics Co., Ltd. Primary endpoint: Adverse Events at 30 days. Started Apr 2024; status: completed.
02
Drugs
Reinovax PCV24
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06675032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675032.